|Articles|January 31, 2017
iCardiac Launches Training Standardization Tool
Advertisement
The direct-to-subject videos facilitate consistent and high quality pulmonary testing across trial sites
Rochester, N.Y. - iCardiac Technologies, Inc., a leading centralized core laboratory specializing in respiratory and cardiac safety studies, announced today that it has launched a Direct-to-Subject Pre-Coaching video tool to help minimize the variability in respiratory test data caused by differences in subject technique and technician coaching. The training videos will be embedded in equipment iCardiac sends to all trial sites and are brief enough to be shown to subjects at the beginning of each testing visit.
The videos will not replace but rather augment the coaching efforts of the site-based pulmonary technicians. By providing guidance and a clear demonstration to each subject shortly before he or she performs a spirometry test, the videos ensure that each subject hears critical information – explained in a clear and consistent way – about how to successfully complete a test. Further, the videos serve to assist and provide a timely refresher to less experienced site technicians on how to effectively coach subjects.
This video-based training standardization platform, now available in 20 languages, has already been deployed by iCardiac on a major global study.
Spirometry measures lung function, which is the amount of air inhaled and the rate at which it is expelled from the lungs. The accuracy and consistency of spirometry test results rely heavily on the patient’s understanding of how to optimally perform the test, and the knowledge and consistency of the medical professional at the site that is coaching that subject through the test.
While performing this test, subjects often make common errors such as a poor breathing effort, incomplete exhalation, or improper use of the equipment. Consistent and effective spirometry testing are critical to the overall outcome and reliability of a clinical trial.
“From the over 250 respiratory clinical trials that we have performed, it is clear that a leading source of test data variability is the variation of coaching styles and knowledge among medical technicians at different clinical sites,” said John Sage, Senior Vice President of Respiratory & eCOA at iCardiac Technologies. “This tool directly and effectively addresses this common issue.”
“We drew upon principles from the fields of cognitive learning, technology-enhanced instruction and psychology to develop this simple but powerful solution,” said Alex Zapesochny, President & CEO of iCardiac Technologies. “And it is being embraced not only by sponsors but also by many site technicians and study subjects for simplifying and improving the overall clinical trial experience.”
About iCardiac Technologies
iCardiac Technologies, Inc. is an industry-leading centralized core laboratory for respiratory and cardiac safety testing services. It has conducted some of the industry’s largest global respiratory studies and has a history of driving innovation across cardiac safety and pulmonary testing. The company serves 8 of the top 10 global pharmaceutical companies, as well as numerous small and mid-sized pharma and biotechnology firms. For more information, please visit:www.icardiac.com .
Rochester, N.Y. - iCardiac Technologies, Inc., a leading centralized core laboratory specializing in respiratory and cardiac safety studies, announced today that it has launched a Direct-to-Subject Pre-Coaching video tool to help minimize the variability in respiratory test data caused by differences in subject technique and technician coaching. The training videos will be embedded in equipment iCardiac sends to all trial sites and are brief enough to be shown to subjects at the beginning of each testing visit.
The videos will not replace but rather augment the coaching efforts of the site-based pulmonary technicians. By providing guidance and a clear demonstration to each subject shortly before he or she performs a spirometry test, the videos ensure that each subject hears critical information – explained in a clear and consistent way – about how to successfully complete a test. Further, the videos serve to assist and provide a timely refresher to less experienced site technicians on how to effectively coach subjects.
This video-based training standardization platform, now available in 20 languages, has already been deployed by iCardiac on a major global study.
Spirometry measures lung function, which is the amount of air inhaled and the rate at which it is expelled from the lungs. The accuracy and consistency of spirometry test results rely heavily on the patient’s understanding of how to optimally perform the test, and the knowledge and consistency of the medical professional at the site that is coaching that subject through the test.
While performing this test, subjects often make common errors such as a poor breathing effort, incomplete exhalation, or improper use of the equipment. Consistent and effective spirometry testing are critical to the overall outcome and reliability of a clinical trial.
“From the over 250 respiratory clinical trials that we have performed, it is clear that a leading source of test data variability is the variation of coaching styles and knowledge among medical technicians at different clinical sites,” said John Sage, Senior Vice President of Respiratory & eCOA at iCardiac Technologies. “This tool directly and effectively addresses this common issue.”
“We drew upon principles from the fields of cognitive learning, technology-enhanced instruction and psychology to develop this simple but powerful solution,” said Alex Zapesochny, President & CEO of iCardiac Technologies. “And it is being embraced not only by sponsors but also by many site technicians and study subjects for simplifying and improving the overall clinical trial experience.”
About iCardiac Technologies
iCardiac Technologies, Inc. is an industry-leading centralized core laboratory for respiratory and cardiac safety testing services. It has conducted some of the industry’s largest global respiratory studies and has a history of driving innovation across cardiac safety and pulmonary testing. The company serves 8 of the top 10 global pharmaceutical companies, as well as numerous small and mid-sized pharma and biotechnology firms. For more information, please visit:
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Ensuring Digital Trial Platforms Work for Underserved Communities
September 10th 2025
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
2
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
3
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
4
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
5